▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AUSTRALIAN PRODUCT INFORMATION – LUXTURNA® (VORETIGENE NEPARVOVEC) SOLUTION FOR SUBRETINAL INJECTION

1 NAME OF THE MEDICINE

Voretigene neparvovec (recombinant adeno-associated virus 2 vector AAV2-Hrpe65V2).

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Voretigene neparvovec is a gene transfer vector that employs an adeno-associated viral vector serotype 2 (AAV2) capsid as a delivery vehicle for the human retinal pigment epithelium 65 kDA protein (hRPE65) cDNA to the retina. Voretigene neparvovec is derived from naturally occurring AAV using recombinant DNA techniques.

Luxturna concentrate for subretinal injection contains 5×10^{12} vector genomes (vg) per mL.

Luxturna is supplied in a 2 mL single-dose vial containing 0.5 mL extractable volume that requires a 1:10 dilution prior to administration.

After dilution, each dose contains 1.5×10^{11} vg in a deliverable volume of 0.3 mL.

For the full list of the excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM

Concentrated solution for subretinal injection.

Both the concentrate and the diluent are clear, colourless preservative-free liquids.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Luxturna is indicated for the treatment of patients with inherited retinal dystrophy caused by pathological biallelic *RPE65* mutations and who have sufficient viable retinal cells as determined by the treating physician.

Pathological mutations of *RPE65* should be confirmed by a National Association of Testing Authorities (NATA) or International Laboratory Accreditation Cooperation (ILAC) accredited laboratory.

4.2 Dose and Method of Administration

Dosage

Treatment should be initiated and administered by a retinal surgeon experienced in performing macular surgery.

Patients will receive a single dose of 1.5 x 10^{11} vg of Luxturna in each eye. Each dose will be delivered into the subretinal space in a total volume of 0.3 mL. The individual administration procedure to each eye is performed on separate days within a close interval, but no fewer than 6 days apart.

Immunomodulatory regimen

Prior to initiation of the immunomodulatory regimen and prior to administration of Luxturna, the patient must be checked for symptoms of active infectious disease of any nature, and in case of such infection the start of treatment must be postponed until after the patient has recovered.

Starting 3 days prior to the administration of Luxturna to the first eye, it is recommended that an immunomodulatory regimen is initiated following the schedule outlined in Table 1. Initiation of the immunomodulatory regimen for the second eye should follow the same schedule and supersede completion of the immunomodulatory regimen of the first eye.

Table 1 Pre- and post-operative immunomodulatory regimen

Pre-operative	3 days prior to administration	Prednisone (or equivalent) 1 mg/kg/day (maximum of 40 mg/day)
Post-operative	4 days (including the day of administration)	Prednisone (or equivalent) 1 mg/kg/day (maximum of 40 mg/day)
	Followed by 5 days	Prednisone (or equivalent) 0.5 mg/kg/day (maximum of 20 mg/day)

	Followed by 5 days of one dose every other day	Prednisone (or equivalent) 0.5 mg/kg every other day (maximum of 20 mg/day)

Method of administration

Subretinal use only. Luxturna is for single use in one patient only. Discard any residue in compliance with institutional guidelines for genetically modified organisms or clinical biohazard waste, as appropriate.

Surgeons should advise patients on the appropriate means of disposing of dressings, waste materials with tears and nasal secretions in the 14 days post-surgery. Patients and caregivers should be advised to wear gloves during dressing changes and place waste materials in a sealed bag for disposal. Patients should be advised to dispose of the sealed bags either through clinical biohazard containers but, if not available, the sealed bags may be placed in normal household waste.

Precautions to be taken before manipulation or administering the medicinal product

This medicinal product contains genetically modified organisms. Personal equipment (to include laboratory coat, safety glasses and gloves) should be worn while preparing or administering voretigene neparvovec (see Section 6.6 SPECIAL PRECAUTIONS OF DISPOSAL).

Administration

Prepare Luxturna within 4 hours of administration using sterile technique under aseptic conditions in a Class II vertical laminar flow biological safety cabinet (BSC). Below is the list of items required for dilution of the concentrate and preparation of the administration syringe:

- One single-dose vial of Luxturna
- Two vials of Diluent
- One 3-mL sterile syringe
- One 20G 1-inch sterile needle
- Three 1-mL sterile syringes
- Three 27G ½-inch sterile needles
- Two sterile syringe caps
- One 10-mL sterile empty glass vial

- One sterile utility drape
- One sterile plastic bag
- Two sterile labels for administration syringes
- One sterile plain label
- Two sterile skin markers.

Dilution of Luxturna

1. Thaw one single-dose vial of Luxturna and two vials of Diluent at temperatures below 30° C (room temperature).
2. Mix the contents of the thawed Diluent vials by gently inverting them approximately 5 times.
3. Inspect the Diluent vials. If particulates, cloudiness, or discolouration are visible, do not use the vial(s); new vial(s) of Diluent should be used.
4. Obtain a 3-mL sterile syringe, a 20G 1-inch sterile needle, and a 10-mL sterile empty glass vial.
5. Using the 3-mL syringe with 20G 1-inch needle, transfer 2.7 mL of Diluent to the 10-mL glass vial. Dispose of the needle and syringe in an appropriate container.
6. Mix the contents of the thawed Luxturna single-dose vial by gently inverting approximately 5 times.
7. Inspect the Luxturna single-dose vial. If particulates, cloudiness, or discolouration are visible, do not use the vial; a new single-dose vial of Luxturna should be used.
8. Obtain a 1-mL sterile syringe and 27 G ½-inch sterile needle. Draw 0.3 mL of Luxturna into a 1-mL sterile syringe with a 27G ½-inch sterile needle (Figure 1).

Figure 1 Syringe with 0.3 mL Luxturna



9. Transfer 0.3 mL of Luxturna to the 10-mL glass vial containing 2.7 mL of Diluent from Step 5. Gently invert the glass vial approximately 5 times to mix the contents.

10. Using the sterile plain label and sterile skin marker, label the 10-mL glass vial containing the diluted Luxturna as follows: 'Diluted Luxturna'.

11. Remove all items from the BSC except the glass vial labeled 'Diluted Luxturna'.

12. Re-sanitise the BSC prior to the next steps and place the glass vial to the left side in the BSC.

Preparation of Luxturna for Injection

To keep the syringes sterile, two operators are required for transfer of the contents of the 10-mL glass vial labeled 'Diluted Luxturna' into each of two sterile 1-mL syringes.

13. Place a sterile utility drape, a sterile plastic bag, and two sterile labels into the BSC.

14. Place the sterile drape near the Primary Operator on the right side of the sanitised BSC surface, away from the diluted Luxturna.

15. The Secondary Operator unwraps two 1-mL syringes, two 27G ½-inch needles, one sterile skin marker and two syringe caps in the BSC, ensuring that the Primary Operator touches only sterile surfaces while transferring the items onto the sterile drape.

16. The Secondary Operator changes to a new pair of sterile gloves and stands or sits to the left of the Primary Operator. The Secondary Operator holds the 10-mL glass vial containing the diluted Luxturna (Figure 2).

Figure 2 First position of the operators during preparation of Luxturna syringes



17. The Primary Operator withdraws 0.8 mL of the diluted Luxturna into a sterile 1-mL syringe using a 27G ½-inch sterile needle while the secondary operator holds the 10-mL glass vial. After the insertion of the needle, the Secondary Operator inverts the 10-mL glass vial enabling the Primary Operator to withdraw 0.8 mL without touching the 10-mL glass vial (Figure 3).

Figure 3 Second position of the operators during preparation of Luxturna syringes



18. The Primary Operator removes the needle and affixes a sterile cap to the sterile syringe, disposes of the needle in an appropriate container, and attaches a sterile label to the administration syringe.

19. The Primary Operator repeats Steps 17 and 18 to prepare a total of two administration syringes. Label the first syringe “Diluted Luxturna” and label the second syringe “Back-up Diluted Luxturna” using the sterile skin marker. The second syringe will serve as a back-up for the surgeon performing the subretinal administration procedure. Discard the back-up syringe after surgery if not used.

20. Inspect both syringes. If particulates, cloudiness, or discolouration are visible, do not use the syringe.

21. Place the syringes into the sterile plastic bag after visual inspection and seal the bag.

22. Place the sterile plastic bag with syringes containing diluted Luxturna into an appropriate secondary container (e.g., hard plastic cooler) for delivery to the surgical suite at room temperature.

Administration

Luxturna should be administered in the surgical suite under controlled aseptic conditions by a surgeon experienced in performing intraocular surgery. In addition to the syringe containing the diluted Luxturna, the following items are required for administration (Figure 4):

- Subretinal injection cannula with a polyamide micro tip with an inner diameter of 41 gauge.
- Extension tube made of polyvinyl chloride no longer than 15.2 cm (6”) in length and with an inner diameter no greater than 1.4 mm**.**

Figure 4 Injection apparatus assembly



Follow the steps below for subretinal injection:

1. After confirming the availability of Luxturna, dilate the eye and give adequate anesthesia to the patient.

2. Administer a topical broad spectrum microbiocide to the conjunctiva, cornea and eyelids prior to surgery.

3. Inspect Luxturna prior to administration. If particulates, cloudiness, or discolouration are visible, do not use the product.

4. Connect the syringe containing the diluted Luxturna to the extension tube and subretinal injection cannula. To avoid excess priming volume, the extension tube should not exceed 15.2 cm in length and 1.4 mm in inner diameter. Inject the product slowly

through the extension tube and the subretinal injection cannula to eliminate any air bubbles.

5. Confirm the volume of product available in the syringe for injection, by aligning the plunger tip with the line that marks 0.3 mL (Figure 5).

Figure 5 Volume of Luxturna for injection



6. After completing a vitrectomy, identify the intended site of administration. The subretinal injection cannula can be introduced via pars plana (Figure 6)

7. Under direct visualisation, place the tip of the subretinal injection cannula in contact with the retinal surface. The recommended site of injection is located along the superior vascular arcade, at least 2 mm distal to the center of the fovea (Figure 7), avoiding direct contact with the retinal vasculature or with areas of pathologic features, such as dense atrophy or intraretinal pigment migration. Inject a small amount of the product slowly until an initial subretinal bleb is observed. Then inject the remaining volume slowly until the total 0.3 mL is delivered.

Figure 6 Subretinal injection cannula introduced via pars plana



Figure 7 Tip of the subretinal injection cannula placed with the recommended site of injection (surgeon's point of view)



8. After completing the injection, remove the subretinal injection cannula from the eye.
9. Following injection, discard all unused product. Dispose of the back-up syringe according to local biosafety guidelines applicable for handling and disposal of the product.
10. Perform a fluid-air exchange, carefully avoiding fluid drainage near the retinotomy created for the subretinal injection.
11. Initiate supine head positioning immediately in the post-operative period.
12. Upon discharge, advise patients to rest in a supine position as much as possible for 24 hours.

Special Populations

Elderly (65 years or above)

The safety and efficacy of voretigene neparvovec in patients ≥65 years old have not been established. However, no adjustment in dosage is necessary for elderly patients.

Hepatic and renal impairment

The safety and efficacy of voretigene neparvovec have not been established in patient with hepatic or renal impairment. No dose adjustment is required in these patients.

Paediatric population (below 18 years of age)

The safety and efficacy of voretigene neparvovec in children below the age of 4 years have not been established. No dose adjustment is necessary for paediatric patients aged 4 years and above.

4.3 Contraindications

- Hypersensitivity to the active substance(s) or to any of the excipients (see Section 6.1 LIST OF EXCIPIENTS).
- Ocular or periocular infection.
- Active intraocular inflammation.

4.4 Special warnings and precautions for use

Endophthalmitis

Endophthalmitis may occur following any intraocular surgical procedure or injection. Use proper aseptic injection technique when administering Luxturna. Following the injection, monitor patients to permit early treatment of any infection. Advise patients to report any signs or symptoms of infection or inflammation without delay.

Patients should avoid swimming because of an increased risk of infection in the eye. Patients may resume swimming after a minimum of one to two weeks, on the advice of their healthcare professional.

Permanent decline in visual acuity

Permanent decline in visual acuity may occur following subretinal injection of Luxturna. Monitor patients for visual disturbances.

Retinal abnormalities

Retinal abnormalities may occur during or following the subretinal injection of Luxturna, including macular holes, foveal thinning, loss of foveal function, foveal dehiscence, and retinal haemorrhage. Monitor and manage these retinal abnormalities appropriately. Do not administer Luxturna in the immediate vicinity of the fovea (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Retinal abnormalities may occur during or following vitrectomy including retinal tears, epiretinal membrane, or retinal detachment. Monitor patients during and following the injection to permit early treatment of these retinal abnormalities. Advise patients to report any signs or symptoms of retinal tears and/or detachment without delay.

Increased intraocular pressure

Increased intraocular pressure may occur after subretinal injection of Luxturna. Monitor and manage intraocular pressure appropriately.

Expansion of intraocular air bubbles

Instruct patients to avoid air travel or travel to high elevations until the air bubble formed following administration of Luxturna has completely dissipated from the eye. A time period of up to one week or more following injection may be required before dissipation of the air bubble. Verify the dissipation of the air bubble through ophthalmic examination. A rapid increase in altitude while the air bubble is still present can cause a rise in eye pressure and irreversible vision loss.

Vector shedding

Transient and low level vector shedding may occur in patient tears (see Section 5.2 PHARMACOKINETIC PROPERTIES, Clinical data).

As a precautionary measure, patients/caregivers should be advised to handle waste material generated from dressings, tears and nasal secretion appropriately, which may include storage of waste material in sealed bags prior to disposal. These handling precautions should be followed for 14 days after administration of Luxturna. It is recommended that patients/caregivers wear gloves for dressing changes and waste disposal, especially in case of underlying pregnancy, breastfeeding and immunodeficiency of caregivers.

Patients treated with Luxturna should not donate blood, organs, tissues and cells for transplantation.

Cataract

Subretinal injection of Luxturna, especially vitrectomy surgery, is associated with an increased incidence of cataract development and/or progression.

Use in hepatic impairment

See Section 4.2 DOSE AND METHOD OF ADMINISTRATION-Special Populations.

Use in renal impairment

See Section 4.2 DOSE AND METHOD OF ADMINISTRATION-Special Populations.

Use in the elderly

See Section 4.2 DOSE AND METHOD OF ADMINISTRATION-Special Populations.

Paediatric use

See Section 4.2 DOSE AND METHOD OF ADMINISTRATION-Special Populations.

Effects on laboratory tests

No data are available.

4.5 Interactions with other medicines and other forms of interactions

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation

Considering the subretinal route of administration of Luxturna, and based on non-clinical and clinical data from trials of AAV2 vectors, there is a very low or negligible risk of inadvertent germ line transmission with AAV vectors.

Effects on fertility

No animal or clinical studies have been conducted to evaluate the effects of voretigene neparvovec on fertility.

Use in pregnancy - Pregnancy Category: B2

There are no adequate and well-controlled studies in pregnant women to inform a product-associated risk.

Embryofetal development studies in animals have not been conducted with voretigene neparvovec.

As a precautionary measure, it is preferable to avoid the use of Luxturna during pregnancy.

Use in lactation

It is not known if voretigene neparvovec is present in human milk. There are no data on the effects of voretigene neparvovec on the breastfed infant or on milk production. A decision must be made whether to discontinue breastfeeding or to abstain from voretigene neparvovec therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.

4.7 Effects on ability to drive and use machines

Voretigene neparvovec has minor influence on the ability to drive and use machines. Patients may experience temporary visual disturbances after receiving subretinal injection of Luxturna. Patients should not drive or use heavy machines until visual function has recovered sufficiently, as advised by their ophthalmologist.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Summary of the safety profile

There were three non-serious adverse reactions of retinal deposits in three of 41 (7%) subjects that were considered to be related to voretigene neparvovec. All three of these events were a transient appearance of asymptomatic subretinal precipitates inferior to the retinal injection site, 1 to 6 days after injection and resolved without sequelae.

Serious adverse reactions related to the administration procedure were reported in three subjects during the clinical program. Increased intraocular pressure, which resulted in optic atrophy, was reported in one subject (1/41; 2%) secondary to administration of depo-steroid given to treat endophthalmitis related to the administration procedure. Retinal disorder (loss of foveal function) and retinal detachment were each reported in one subject each (1/41; 2%).

The most common ocular adverse reactions (incidence ≥5%) related to the administration procedure were conjunctival hyperaemia, cataract, increased intraocular pressure, retinal tear, dellen (thinning of the corneal stroma), macular hole, subretinal deposits, eye inflammation, eye irritation, eye pain, and maculopathy (wrinkling on the surface of the macula).

Tabulated summary of adverse drug reactions from clinical trials

The safety data described in this section reflect exposure to voretigene neparvovec in three clinical trials consisting of 41 subjects (81 eyes) with vision loss due to inherited retinal dystrophy caused by confirmed biallelic *RPE65* mutation. Study 101 (n=12) was a Phase 1 safety and dose escalation study in which 12 subjects received unilateral subretinal injections of voretigene neparvovec. Eleven of the twelve subjects who participated in the dose escalation study went on to receive voretigene neparvovec in the second eye (Study 102). Study 301 (n=29) was an open-label, randomised, controlled study for both efficacy and safety (see Section 5 PHARMACOLOGICAL PROPERTIES, Clinical trials).

In total, 40 of the 41 subjects received sequential subretinal injections of voretigene neparvovec to each eye. One subject received voretigene neparvovec in only one eye. Seventy-two of the 81 eyes were exposed to the recommended dose of Luxturna at 1.5 x 10^{11} vg. In Study 101, 9 eyes were exposed to lower doses of voretigene neparvovec. The average age of the 41 subjects was 17 years ranging from 4 to 44 years. Of the 41 subjects, 25 (61%) were paediatric subjects under 18 years of age, and 23 (56%) were females.

Adverse drug reactions from clinical trials (Table 2) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III):

very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

Adverse reactions may have been related to voretigene neparvovec, the subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products.

Table 2 Percentage of patients with adverse drug reactions in clinical trials

Adverse drug reactions	Voretigene neparvovec			Frequency category
	Study 101 + Study 102 (N = 12 subjects) n (%)	Study 301 (N = 29 subjects) n (%)	Studies 101 + 102 + 301 (N = 41 subjects)* n (%)	
Eye disorders				
Conjunctival hyperaemia[a]	8 (67)	1 (3)	9 (22)	very common
Cataract	3 (25)	5 (17)	8 (20)	very common
Retinal tear	1 (8)	3 (10)	4 (10)[g]	common
Macular hole	1 (8)	2 (7)	3 (7)	common
Retinal deposits[b]	0	3 (10)	3 (7)	common
Dellen	3 (25)	0	3 (7)	common
Eye inflammation	0	2 (7)	2 (5)	common
Maculopathy[c]	1 (8)	1 (3)	2 (5)	common
Eye irritation	1 (8)	1 (3)	2 (5)	common
Eye pain	1 (8)	1 (3)	2 (5)	common
Retinal detachment	0	1 (3)	1 (2)	common
Retinal haemorrhage	0	1 (3)	1 (2)	common

Adverse drug reactions	Voretigene neparvovec			Frequency category
	Study 101 + Study 102 (N = 12 subjects) n (%)	Study 301 (N = 29 subjects) n (%)	Studies 101 + 102 + 301 (N = 41 subjects)* n (%)	
Choroidal haemorrhage	0	1 (3)	1 (2)	common
Endophthalmitis	1 (8)	0	1 (2)	common
Macular degeneration[d]	0	1 (3)	1 (2)	common
Conjunctival cyst	0	1 (3)	1 (2)	common
Eye disorder[e]	1 (8)	0	1 (2)	common
Eye swelling	0	1 (3)	1 (2)	common
Foreign body sensation in the eyes	0	1 (3)	1 (2)	common
Retinal disorder[f]	0	1 (3)	1 (2)	common
Investigations				
Intraocular pressure increased	2 (17)	4 (14)	6 (15)	very common

[a] Includes verbatim terms suture irritation and suture reaction

[b] Includes verbatim term subretinal precipitate

[c] Includes verbatim terms epiretinal membrane and macular pucker

[d] Includes verbatim term macular thinning

[e] Includes verbatim term foveal dehiscence

Adverse drug reactions	Voretigene neparvovec			Frequency category
	Study 101 + Study 102 (N = 12 subjects) n (%)	Study 301 (N = 29 subjects) n (%)	Studies 101 + 102 + 301 (N = 41 subjects)* n (%)	

[f] Includes verbatim terms foveal thinning and loss of foveal function

[g] A frequency categorisation of "common" has been assigned to the event of retinal tear in line with CIOMS III criteria as the unrounded incidence rate was ≥1/100 to <1/10 (9.75%; 4/41)

*ADR frequency is determined by pool of studies 101, 102, and 301

Adverse drug reactions from non-interventional studies, spontaneous reports and literature cases (frequency not known)

The following adverse drug reactions have been derived from post-marketing experience with Luxturna via non-interventional studies, spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.

Eye disorders

Chorioretinal atrophy (includes preferred terms retinal degeneration, retinal depigmentation and injection site atrophy)

Description of selected adverse drug reactions

Chorioretinal atrophy

Chorioretinal atrophy has been reported as an adverse reaction during post-marketing experience and reported as progressive in some patients. Events were temporarily related to treatment and occurred in the estimated treated area of the bleb site and outside the bleb area. Retinal atrophy may involve the fovea with possible negative effects on the central vision.

Immunogenicity

At all doses of Luxturna evaluated in Studies 101 and 301, immune reactions were mild in severity and extra-ocular exposure was limited. In Study 101, the interval between the

subretinal injections into the two eyes ranged from 1.7 to 4.6 years. In Study 301, the interval between the subretinal injections into the two eyes ranged from 7 to 14 days. No subject had a clinically significant cytotoxic T-cell response to either adeno-associated virus serotype 2 [AAV2] vector or retinal pigment epithelial 65 kDa protein [*RPE65*].

Subjects received systemic corticosteroids before and after subretinal injection of Luxturna to each eye. The corticosteroids may have decreased the potential immune reaction to either vector capsid [AAV2] or transgene product [*RPE65*].

Reporting of suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Symptomatic and supportive treatment is advised in case of overdose.

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: other ophthalmologicals SO1XA, ATC code: S01XA27.

Mechanism of action

Luxturna is designed to deliver a normal copy of the gene encoding the human retinal pigment epithelial 65 kDa protein (*RPE65*) to cells of the retina in persons with reduced or absent levels of biologically active *RPE65*. The *RPE65* is produced in the retinal pigment epithelial (RPE) cells and converts all-trans-retinol to 11-cis-retinol, which subsequently forms the chromophore, 11 cis-retinal, during the visual (retinoid) cycle. The visual cycle is critical in phototransduction, which refers to the biological conversion of a photon of light into an electrical signal in the retina. Mutations in the *RPE65* gene lead to reduced or absent levels of *RPE65* isomerohydrolase activity, blocking the visual cycle, resulting in impairment of vision and ultimately complete blindness.

Pharmacodynamics (PD)

Injection of Luxturna into the subretinal space results in transduction of some retinal pigment epithelial cells with a cDNA encoding normal human *RPE65* protein, thus providing the potential to restore the visual cycle.

Clinical trials

Study 301

The efficacy of Luxturna in paediatric and adult patients was evaluated in an open-label, two-centre, randomised trial (Study 301).

Individuals with a confirmed genetic diagnosis of biallelic *RPE65* gene mutations were eligible for enrolment if:

-Both eyes had visual acuity of 20/60 (equivalent to 0.48 logMAR) or worse, and/or visual field less than 20 degrees in any meridian as measured by III4e isopter or equivalent;

-They had sufficient viable retinal cells as determined by either:

-Retinal thickness on spectral domain optical coherence tomography (>100 microns within the posterior pole),

-At least 3 disc areas of the retina without atrophy or pigmentary degeneration within the posterior pole on ophthalmoscopy, or

-Remaining visual field within 30 degrees of fixation as measured by III4e isopter or equivalent.

-They were able to perform a standardised multi-luminance mobility test (MLMT) within the luminance range evaluated, but unable to pass the MLMT at 1 lux, the lowest luminance level tested.

Of the 31 enrolled subjects, 21 subjects were randomised to receive subretinal injection of Luxturna. One subject discontinued from the study prior to treatment. Ten subjects were randomised to the control (non-intervention) group. One subject in the control group withdrew consent and was discontinued from the study. The nine subjects who were randomised to the control group were crossed over to receive subretinal injection of Luxturna after one year of observation. The average age of the 31 randomised subjects was 15 years (range 4 to 44 years), including 64% paediatric subjects (n=20, age from 4 to 17 years) and 36% adults (n=11). The average visual acuity at treatment baseline was 1.18 logMAR for the intervention group and 1.29 logMAR for the control. Bilateral subretinal injections of Luxturna were administered sequentially in two separate surgical procedures with an interval of 6 to 18 days.

The efficacy of Luxturna was established on the basis of MLMT score change from Baseline to Year 1.

The MLMT was designed to measure changes in functional vision, as assessed by the ability of a subject to navigate a course accurately and at a reasonable pace at different levels of environmental illumination.

The MLMT was assessed using both eyes (binocular vision) and each eye separately at one or more of seven levels of illumination, ranging from 400 lux (corresponding to a brightly lit office) to 1 lux (corresponding to a moonless summer night). Each light level was assigned a score code ranging from 0 to 6. A higher score indicated that a subject was able to pass the MLMT at a lower light level. The MLMT of each subject was videotaped and assessed by independent graders using a defined combination of speed and accuracy scores. The MLMT score was determined by the lowest light level at which the subject was able to pass the MLMT. The MLMT score change was defined as the difference between the score at Baseline and the score at Year 1. A positive MLMT score change from Baseline to Year 1 visit indicated that the subject was able to complete the MLMT at a lower light level.

Three secondary endpoints were also tested: full-field light sensitivity threshold (FST) testing using white light; the change in MLMT score for the first assigned eye; and visual acuity (VA) testing.

Table 3 summarises the average MLMT score change from Baseline to Year 1 in the Luxturna treatment group compared to the control group.

Table 3 Changes in MLMT score: Year 1, compared to baseline (ITT population: n=21 Intervention, n=10 Control)

Change in MLMT score	**Difference (95% CI) Intervention-Control**	**p-value**
using binocular vision	1.6 (0.72, 2.41)	0.001
using assigned first eye only	1.7 (0.89, 2.52)	0.001
using assigned second eye only	2.0 (1.14, 2.85)	<0.001

Figure 8 shows MLMT performance of individual subjects using both eyes at Baseline and at Year 1.

Figure 8 MLMT score using both eyes at baseline and one year for individual subjects



Note for Figure 8: **subjects who were withdrawn or discontinued. The open circles are the baseline scores. The closed circles are the Year 1 scores. The numbers next to the solid circle represent score change at Year 1. The horizontal lines with arrows represent the magnitude of the score change and its direction. Arrows pointing towards the right represent improvement. The top section shows the results of the 21 subjects in the treatment group. The bottom section shows the results of the 10 subjects in the control group. Subjects in each group are chronologically organised by age, with the youngest subject at the top and the oldest subject at the bottom.*

Figure 9 shows the effect of the medicinal product over the three-year period in the voretigene neparvovec treatment group, as well as the effect in the control group after crossing over to receive subretinal injection of voretigene neparvovec. Significant

differences in binocular MLMT performance were observed for the voretigene neparvovec treatment group at day 30 and were maintained over the remaining follow up visits throughout the three year period, compared to no change in the control group. However, after crossing over to receive subretinal injection of voretigene neparvovec, the subjects in the control group showed a similar response to the voretigene neparvovec as compared to the subjects in the voretigene neparvovec treatment group.

Figure 9 Change in MLMT score using binocular vision versus time before/after exposure to voretigene neparvovec



Note for Figure 9: *Each box represents the middle 50% of distribution of MLMT score change. Vertical dotted lines represent additional 25% above and below the box. The horizontal bar within each box represents the median. The dot within each box represents the mean. The solid line connects the mean MLMT score changes over visits for the treatment group. The dotted line connects the mean MLMT score change over visits for the Control group, including five visits during the first year without receiving voretigene neparvovec. The control group was administered voretigene neparvovec after 1 year of observation.*

BL: baseline;

D30, D90, D180: 30, 90 and 180 days after start of study;

Y1, Y2, Y3: one, two and three years after start of study;

XBL; XD30; XD90; XD180: baseline, 30, 90 and 180 days after start of study for Control crossover group;

XY1; XY2: one and two years after start of study for Control crossover group.

FST testing is a global measure of retinal sensitivity to light, whereby Log10 (cd.s/m2) values indicate better sensitivity the more negative they are. Results of full-field light sensitivity testing at the first study year: white light [Log10 (cd.s/m2)] are shown in Table 5 below.

Table 4 Full field light sensitivity testing

Full-field light sensitivity testing - First assigned eye (ITT)			
	Intervention, N = 21		
	Baseline	**Year 1**	**Change**
N	20	20	19
Mean (SE)	-1.23 (0.10)	-3.44 (0.30)	-2.21 (0.30)
	Control, N = 10		
N	9	9	9
Mean (SE)	-1.65 (0.14)	-1.54 (0.44)	0.12 (0.45)
	Difference (95% CI) (Intervention-Control) -2.33 (-3.44, -1.22), p<0.001		
Full-field light sensitivity testing - Second assigned eye (ITT)			
	Intervention, N = 21		
	Baseline	**Year 1**	**Change**
N	20	20	19

Mean (SE)	-1.35 (0.09)	-3.28 (0.29)	-1.93 (0.31)
	Control, N = 10		
N	9	9	9
Mean (SE)	-1.64 (0.14)	-1.69 (0.44)	0.04 (0.46)
	Difference (95% CI) (Intervention-Control) -1.89 (-3.03, -0.75), p=0.002		
Full-field light sensitivity testing - Averaged across both eyes (ITT) Difference (95% CI) (Intervention-Control): -2.11 (-3.19, -1.04), p<0.001			

Subjects in the control group who crossed over to receive subretinal injection of voretigene neparvovec at Year 1 had a similar response to voretigene neparvovec as subjects in the original intervention group. For both treatment groups, following vector administration, the gain in FST performance was greater than 2 log units, reflecting more than a 100-fold improvement in light sensitivity. Improvement in full-field light sensitivity was maintained for up to 3 years after exposure to voretigene neparvovec.

A supportive analysis showed that the linear relationships between the MLMT scores and FST in this study were generally good to strong, indicating that subjects with improvement on mobility testing at Year 1 tended to have lower (i.e. better) FST results at Year 1.

At one year after exposure to voretigene neparvovec, the mean change from baseline in visual acuity across both eyes using the Holladay scale was -0.16 LogMAR for the intervention group, and 0.01 LogMAR for the untreated control group. This reflected a mean 8 ETDRS-letter improvement for intervention subjects, compared to a mean 0.5-letter loss for control subjects. This difference between groups was not statistically significant.

In a supportive post hoc analysis using the Lange scale for off-chart scoring, the intervention group showed a 9.0 letter improvement versus a 1.5 letter improvement in the control group, averaged over both eyes (difference of 7.5 letters). This difference between groups was statistically significant.

5.2 Pharmacokinetic properties

Pharmacokinetics (PK)

Biodistribution (within the body) and Vector Shedding (excretion/secretion)

Luxturna vector DNA levels in various tissues and secretions were determined using a quantitative polymerase chain reaction (qPCR) assay.

Nonclinical data

Biodistribution of voretigene neparvovec was evaluated at three months following subretinal administration in non-human primates. The highest levels of vector DNA sequences were detected in intraocular fluids (anterior chamber fluid and vitreous) of vector-injected eyes. Low levels of vector DNA sequences were detected in the optic nerve of the vector-injected eye, optic chiasm, spleen and liver, and sporadically in the lymph nodes. Vector DNA sequences were not detected in the gonads.

Clinical data

Luxturna vector shedding and biodistribution were investigated in a study measuring Luxturna DNA in tears from both eyes, and from serum, and whole blood of subjects in Study 301. In summary, Luxturna vector was shed transiently and at low levels in tears from the injected eye in 45% of the subjects in Study 301, and occasionally (7%) from the uninjected eye until Day 3 post-injection.

In 29 subjects who received bilateral administrations, Luxturna vector DNA was present in tear samples of 13 subjects (45%). Peak levels of vector DNA were detected in the tear samples on Day 1 post-injection, after which no vector DNA was detected in a majority of the subjects (8 of 13). Three subjects (10%) had vector DNA in tear samples until Day 3 post-injection, and one subject (3%) had vector DNA in tear samples until Day 14 post-injection. In another two subjects (7%), vector DNA was detected in tear samples from the uninjected (or previously injected) eye until Day 3 post-injection. Vector DNA was detected in serum in 3/29 (10%) subjects, including two with vector DNA in tear samples up to Day 3 following each injection.

5.3 Preclinical safety data

Bilateral, simultaneous subretinal administration of voretigene neparvovec was well tolerated at dose levels up to 8.25×10^{10} vg per eye in dogs with a naturally occurring *RPE65* mutation and 7.5×10^{11} vg (5 times higher than the recommended human dose level) per eye in monkeys with normal-sighted eyes. In both animal models, bilateral, sequential subretinal administrations, where the contralateral eye was injected following the first eye, were well tolerated at the recommended human dose level of 1.5×10^{11} vg per eye. In addition, dogs with the *RPE65* mutation displayed improved visual behaviour and pupillary responses.

Ocular histopathology of dog and non-human primate (monkey) eyes exposed to voretigene neparvovec showed only mild changes, which were mostly related to healing from surgical injury that expressed minimal RPE65 protein. In an earlier toxicology study, a similar AAV2 vector administered subretinally in dogs at a dose of 10 times the recommended dose resulted in focal retinal toxicity and inflammatory cell infiltrates histologically in regions exposed to the vector. Other findings in dogs and monkeys injected subretinally with voretigene neparvovec included occasional and isolated inflammatory cells in the retina, with no apparent retinal degeneration. Following a single vector administration, dogs developed antibodies to the AAV2 vector capsid whereas monkeys did not.

Genotoxicity

No genotoxicity studies have been conducted with voretigene neparvovec. The risk of insertional mutagenesis with voretigene neparvovec is considered to be low. Voretigene neparvovec lacks the AAV wildtype Rep proteins that catalyse site-specific viral genome integration.

Carcinogenicity

No animal carcinogenicity studies have been conducted with voretigene neparvovec.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Concentrate

Sodium chloride, monobasic sodium phosphate (for pH adjustment), dibasic sodium phosphate (for pH adjustment), poloxalene, water for injections.

Diluent

Sodium chloride, monobasic sodium phosphate (for pH adjustment), dibasic sodium phosphate (for pH adjustment), poloxalene, water for injections.

6.2 Incompatibilities

In the absence of compatibility studies, this product must not be mixed with other medicinal products.

6.3 Shelf life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special precautions for storage

Concentrate and diluent

Must be stored frozen at ≤-65˚C.

After thawing

Once thawed, the medicinal product should not be re-frozen and should be left at room temperature (below 25 °C).

Following dilution under aseptic conditions

The solution must be used immediately; if not used immediately, the storage time at room temperature (below 25 °C) should be no longer than 4 hours.

6.5 Nature and contents of container

0.5 mL extractable volume of concentrate in 2 mL cyclic olefin polymer vial with a chlorobutyl rubber stopper sealed in place with an aluminium flip-off seal.

1.7 mL extractable volume of solvent in a 2 mL cyclic olefin polymer vial with a chlorobutyl rubber stopper sealed in place with an aluminium flip-off seal.

Each foil pouch includes a carton containing 1 vial of concentrate and 2 vials of solvent.

6.6 Special precautions for disposal

Special precautions for disposal

This medicine contains genetically modified organisms. Unused medicine and waste products must be disposed of in compliance with the institutional guidelines for genetically modified organisms or clinical biohazardous waste, as appropriate.

6.7 Physicochemical properties

CAS number

1646819-03-5.

7 MEDICINE SCHEDULE (POISONS STANDARD)

Not determined.

8 SPONSOR

Novartis Pharmaceuticals Australia Pty Limited

ABN 18 004 244 160

54 Waterloo Road

Macquarie Park NSW 2113.

1800 671 203.

® = Registered Trademark.

9 DATE OF FIRST APPROVAL

5 August 2020

10 DATE OF REVISION

11 November 2025

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.2	Editorial update to dose and administration section as per revised pharmacy manual
4.8	Updated to add description of 'chorioretinal atrophy'
5.2	Updated description of "vector shedding" results

Internal document code: lux111125i based on CDS dated 12 August 2025